The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis

Clinical Immunology

Volumn 173, Issue , 2016, Pages 76-80

  Cossu, Marta ^a   van Bon, Lenny ^a   Nierkens, Stefan ^a   Bellocchi, Chiara ^b   Santaniello, Alessandro ^b   Dolstra, Harry ^c   Beretta, Lorenzo ^b   Radstake, Timothy R D J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD56+ cells; Cytokines; Early systemic sclerosis; Systemic sclerosis; Toll like receptors

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR; CYTOKINE; NCAM1 PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; INNATE IMMUNITY; MALE; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; AGED; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; AGED; ANTIGENS, CD56; CYTOKINES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2;

EID: 84992332527     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.09.004     Document Type: Article

References (24)

1. [1] Gabrielli, A., Avvedimento, E.V., Krieg, T., Scleroderma. N. Engl. J. Med. 360 (2009), 1989–2003.
2. [2] van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., Matucci-Cerinic, M., Naden, R.P., Medsger, T.A. Jr., Carreira, P.E., Riemekasten, G., Clements, P.J., Denton, C.P., Distler, O., Allanore, Y., Furst, D.E., Gabrielli, A., Mayes, M.D., van Laar, J.M., Seibold, J.R., Czirjak, L., Steen, V.D., Inanc, M., Kowal-Bielecka, O., Muller-Ladner, U., Valentini, G., Veale, D.J., Vonk, M.C., Walker, U.A., Chung, L., Collier, D.H., Csuka, M.E., Fessler, B.J., Guiducci, S., Herrick, A., Hsu, V.M., Jimenez, S., Kahaleh, B., Merkel, P.A., Sierakowski, S., Silver, R.M., Simms, R.W., Varga, J., Pope, J.E., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 65 (2013), 2737–2747.
3. [3] Vigone, B., Santaniello, A., Marchini, M., Montanelli, G., Caronni, M., Severino, A., Beretta, L., Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosis. Rheumatology (Oxford) 54 (2015), 707–711.
4. [4] Koenig, M., Joyal, F., Fritzler, M.J., Roussin, A., Abrahamowicz, M., Boire, G., Goulet, J.R., Rich, E., Grodzicky, T., Raymond, Y., Senecal, J.L., Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58 (2008), 3902–3912.
5. [5] Valentini, G., Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). Autoimmun. Rev. 14 (2015), 210–213.
6. [6] LeRoy, E.C., Medsger, T.A. Jr., Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28 (2001), 1573–1576.
7. [7] van Bon, L., Cossu, M., Radstake, T.R., An update on an immune system that goes awry in systemic sclerosis. Curr. Opin. Rheumatol. 23 (2011), 505–510.
8. [8] Fullard, N., O'Reilly, S., Role of innate immune system in systemic sclerosis. Semin. Immunopathol. 37 (2015), 511–517.
9. [9] Brkic, Z., van Bon, L., Cossu, M., van Helden-Meeuwsen, C.G., Vonk, M.C., Knaapen, H., van den Berg, W., Dalm, V.A., Van Daele, P.L., Severino, A., Maria, N.I., Guillen, S., Dik, W.A., Beretta, L., Versnel, M.A., Radstake, T., The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann. Rheum. Dis., 2015.
10. [10] van Bon, L., Affandi, A.J., Broen, J., Christmann, R.B., Marijnissen, R.J., Stawski, L., Farina, G.A., Stifano, G., Mathes, A.L., Cossu, M., York, M., Collins, C., Wenink, M., Huijbens, R., Hesselstrand, R., Saxne, T., DiMarzio, M., Wuttge, D., Agarwal, S.K., Reveille, J.D., Assassi, S., Mayes, M., Deng, Y., Drenth, J.P., de Graaf, J., den Heijer, M., Kallenberg, C.G., Bijl, M., Loof, A., van den Berg, W.B., Joosten, L.A., Smith, V., de Keyser, F., Scorza, R., Lunardi, C., van Riel, P.L., Vonk, M., van Heerde, W., Meller, S., Homey, B., Beretta, L., Roest, M., Trojanowska, M., Lafyatis, R., Radstake, T.R., Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370 (2014), 433–443.
11. [11] Lunemann, A., Lunemann, J.D., Munz, C., Regulatory NK-cell functions in inflammation and autoimmunity. Mol. Med. 15 (2009), 352–358.
12. [12] Chan, W.K., Rujkijyanont, P., Neale, G., Yang, J., Bari, R., Das Gupta, N., Holladay, M., Rooney, B., Leung, W., Multiplex and genome-wide analyses reveal distinctive properties of KIR + and CD56 + T cells in human blood. J. Immunol. 191 (2013), 1625–1636.
13. [13] Almeida, I., Silva, S.V., Fonseca, A.R., Silva, I., Vasconcelos, C., Lima, M., T and NK cell phenotypic abnormalities in systemic sclerosis: a cohort study and a comprehensive literature review. Clin. Rev. Allergy Immunol. 49 (2015), 347–369.
14. [14] Maverakis, E., Patel, F., Kronenberg, D.G., Chung, L., Fiorentino, D., Allanore, Y., Guiducci, S., Hesselstrand, R., Hummers, L.K., Duong, C., Kahaleh, B., Macgregor, A., Matucci-Cerinic, M., Wollheim, F.A., Mayes, M.D., Gershwin, M.E., International consensus criteria for the diagnosis of Raynaud's phenomenon. J. Autoimmun. 48-49 (2014), 60–65.
15. [15] Clements, P.J., Lachenbruch, P.A., Seibold, J.R., Zee, B., Steen, V.D., Brennan, P., Silman, A.J., Allegar, N., Varga, J., Massa, M., et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J. Rheumatol. 20 (1993), 1892–1896.
16. [16] Goh, N.S., Desai, S.R., Veeraraghavan, S., Hansell, D.M., Copley, S.J., Maher, T.M., Corte, T.J., Sander, C.R., Ratoff, J., Devaraj, A., Bozovic, G., Denton, C.P., Black, C.M., du Bois, R.M., Wells, A.U., Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177 (2008), 1248–1254.
17. [17] de Jager, W., te Velthuis, H., Prakken, B.J., Kuis, W., Rijkers, G.T., Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10 (2003), 133–139.
18. [18] Schleinitz, N., Vely, F., Harle, J.R., Vivier, E., Natural killer cells in human autoimmune diseases. Immunology 131 (2010), 451–458.
19. [19] Kamath, A.T., Sheasby, C.E., Tough, D.F., Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 174 (2005), 767–776.
20. [20] Cossu, M., Andracco, R., Santaniello, A., Marchini, M., Severino, A., Caronni, M., Radstake, T., Beretta, L., Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients. Rheumatology (Oxford), 2016.
21. [21] Codullo, V., Baldwin, H.M., Singh, M.D., Fraser, A.R., Wilson, C., Gilmour, A., Hueber, A.J., Bonino, C., McInnes, I.B., Montecucco, C., Graham, G.J., An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann. Rheum. Dis. 70 (2011), 1115–1121.
22. [22] Broen, J.C., Bossini-Castillo, L., van Bon, L., Vonk, M.C., Knaapen, H., Beretta, L., Rueda, B., Hesselstrand, R., Herrick, A., Worthington, J., Hunzelman, N., Denton, C.P., Fonseca, C., Riemekasten, G., Kiener, H.P., Scorza, R., Simeon, C.P., Ortego-Centeno, N., Gonzalez-Gay, M.A., Airo, P., Coenen, M.J., Martin, J., Radstake, T.R., A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum. 64 (2012), 264–271.
23. [23] Lauzon, N.M., Mian, F., MacKenzie, R., Ashkar, A.A., The direct effects of toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell. Immunol. 241 (2006), 102–112.
24. [24] Lu, H., Yang, Y., Gad, E., Inatsuka, C., Wenner, C.A., Disis, M.L., Standish, L.J., TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin. Cancer Res. 17 (2011), 6742–6753.